# Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

> **NCT05263882** · PHASE2 · UNKNOWN · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 58 (estimated)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Gemcitabine combined with eribulin

## Key facts

- **NCT ID:** NCT05263882
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03
- **Primary completion:** 2023-12
- **Final completion:** 2024-09
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263882, "Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05263882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*